EYVIS PADIN: Open Payments
NPI 1790562932 · SUFFOLK, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$426 in 19 payments from 15 companies in 2025. Trend: 2023 $226 · 2024 $2,116 · 2025 $426
Food & beverage: $426
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 2 | $48 |
| Incyte Corporation | 2 | $45 |
| Daiichi Sankyo Inc. | 2 | $39 |
| Genentech USA, Inc. | 1 | $35 |
| ADC THERAPEUTICS AMERICA, INC. | 2 | $33 |
| Novartis Pharmaceuticals Corporation | 1 | $29 |
| GENZYME CORPORATION | 1 | $28 |
| Merck Sharp & Dohme LLC | 1 | $27 |
| JAZZ PHARMACEUTICALS INC. | 1 | $25 |
| ABBVIE INC. | 1 | $24 |
Products named: Polivy, ZYNLONTA, Vyloy, KISQALI, SARCLISA, KEYTRUDA, ZEPZELCA, JAKAFI.
Industry payments across VA — which companies pay providers there.
